Search earnings tickers

ALNY

2026Q2BMO

Alnylam Pharmaceuticals Inc primary · HEALTHCARE · BIOTECHNOLOGY

Report 2026-07-30 · Fiscal end 2026-06-30 · Features as of 2026-07-29

← Earnings history

Street

Consensus EPS1.44

Consensus rev—

EPS high—

EPS low—

Dispersion—

Analysts—

EPS rev net 7d—

EPS rev net 30d—

Consensus Δ 7d—

Consensus Δ 30d—

Options

Implied move3.0%

IV front—

P/C full—

P/C front—

Features as of2026-07-29

Run-up

Close—

Ret 5d+7.4%

Ret 10d+2.7%

Ret 20d-4.8%

Ret 30d-0.4%

Print

Actual EPS

1.21Miss

Estimated EPS1.44

Actual revenue

1.3B

Surprise %-16.0%

Beat / missMiss

Beat streak 40

Beat streak 80

Reaction

1-day stock reaction-8.7%

Implied vs actual

Implied 3.0%Actual 21.5%

Gap reaction-21.5%

Day result-28.3%

Next-day upNo

Realized / IV7.13×

Post tape

Post 5d+5.2%

Post 10d+10.5%

Post volume9.8M

Vol ×10d7.74×

Vol ×20d6.33×

Post range14.3%